Can we prevent immunogenicity of human protein drugs?

D. W. Scott, A. S. De Groot

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Monoclonal antibodies have proved to be extremely valuable additions to conventional treatment for rheumatic diseases. However, despite the general trend towards "humanisation", these drugs remain immunogenic in clinical settings, baffling drug developers. In principle, humanised and fully human monoclonal antibodies are "self" immunoglobulins and should be tolerated. In this overview, the factors that may influence this process, the nature of immunogenicity and methods to analyse and modify potential immunogenicity are discussed. Finally, novel approaches to "re-induce" immunological tolerance to these proteins, including gene therapy and the recognition of unique regulatory epitopes, are outlined.

Original languageEnglish
Pages (from-to)i72-i76
JournalAnnals of the Rheumatic Diseases
Issue numberSUPPL. 1
StatePublished - Jan 2010


Dive into the research topics of 'Can we prevent immunogenicity of human protein drugs?'. Together they form a unique fingerprint.

Cite this